A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma

Cancer

Volumn 123, Issue 4, 2017, Pages 576-582

  Pal, Sumanta K ^a   Drabkin, Harry A ^b   Reeves, James A ^c   Hainsworth, John D ^d   Hazel, Susan E ^e   Paggiarino, Dario A ^e   Wojciak, Jon ^e   Woodnutt, Gary ^e   Bhatt, Rupal S ^f  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Sarah Cannon Research Institute/Florida Cancer Specialists   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e Lpath Inc   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

renal cell carcinoma; resistance; sonepcizumab; sphingosine 1 phosphate (S1P)

Indexed keywords

BEVACIZUMAB; CREATININE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; POLYBROMO 1; SONEPCIZUMAB; SPHINGOSINE 1 PHOSPHATE; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VON HIPPEL LINDAU PROTEIN; LYSOPHOSPHOLIPID; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; PBRM1 PROTEIN, HUMAN; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; TRANSCRIPTION FACTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; VHL PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD LEVEL; BONE METASTASIS; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; GENE EXPRESSION PROFILING; HUMAN; HYPOTHYROIDISM; INFUSION RELATED REACTION; INTERMEDIATE RISK POPULATION; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPHOCYTE COUNT; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PATIENT SELECTION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; SURVIVAL TIME; THORAX PAIN; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NUCLEAR PROTEINS; SPHINGOSINE; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84995970138     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30393     Document Type: Article

References (23)

1. Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn DI. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther. 2012;11:526–537.
2. Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010;21:1834–1838.
3. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–1068.
4. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–2524.
5. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137–2143.
6. Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813.
7. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473–1482.
8. Choueiri TK, Escudier B, Powles T, et al; METEOR Investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1814–1823.
9. Zhang L, Wang X, Bullock AJ, et al. Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer. Clin Cancer Res. 2015;21:1925–1934.
10. Deng J, Liu Y, Lee H, et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell. 2012;21:642–654.
11. O'Brien N, Jones ST, Williams DG, et al. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res. 2009;50:2245–2257.
12. Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015;16:293–300.
13. Choueiri TK, Escudier B, Powles T, et al; METEOR Investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:917–927.
14. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
15. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920.
16. Priceman SJ, Shen S, Wang L, et al. S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3. Cell Rep. 2014;6:992–999.
17. Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:286–296.
18. Hammad SM, Pierce JS, Soodavar F, et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res. 2010;51:3074–3087.
19. Tiper IV, East JE, Subrahmanyam PB, Webb TJ. Sphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation, and infection. Pathog Dis. 2016;74(6). pii: ftw063.
20. Ho TH, Kapur P, Joseph RW, et al. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urol Oncol. 2015;33:23.e9–23.e14.
21. Kapur P, Pena-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 2013;14:159–167.
22. Choueiri TK, Fay AP, Gagnon R, et al. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2013;19:5218–5226.
23. Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 2014;32:5010.